Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a pharmacokinetics (PK), open-label, uncontrolled, multicenter phase II trial with age-staggered approach.
The primary objective is to evaluate the PK profile of gadopiclenol in plasma following single IV injection of 0.05 mmol/kg body weight (BW) in pediatric population aged from 2 to 17 years undergoing CNS contrast-enhanced MRI (CNS cohort).
Full description
A population PK approach and an age-down staggered approach will be used. Patients will be recruited into 3 predefined age groups: 12-17, 7-11 and 2-6 years. The inclusions will start with the older group (Adolescents, 12-17 years), followed by Preadolescents (7-11 years) and finally Young Children (2-6 years of age).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
To be included in the study, the patient had to meet all the following criteria:
Non-inclusion Criteria:
Patients could not be included in the study if they presented with one or more of the following non-inclusion criteria:
Patient planned for treatment or procedure (e.g., surgery) that would prevent obtaining the required blood samples or performing other trial procedures between the screening visit and up to 1 day after gadopiclenol administration,
Patient undergoing treatment or procedure (e.g., diuretics, clinically significant blood loss or blood transfusion) preceding or subsequent to gadopiclenol administration that would alter gadopiclenol PK parameters,
Patient with acute or chronic renal insufficiency defined as estimated Glomerular Filtration Rate (eGFR) out of age-adjusted normal ranges (eGFR calculated with bedside Schwartz equation),
Patients referred for MR Angiography,
Patient with history of bleeding disorder,
Patient with known severe liver disease,
Patient with known cardiac disease (e.g., heart rhythm anomalies, long QT syndrome),
Patient with any clinically significant abnormal 12-lead ECG that in the Investigator's opinion would affect the safety evaluation or place the patient at risk,
Patient with electrolyte or fluid imbalance that at Investigator's judgment presents undue risk assessed within 1 month prior to gadopiclenol administration,
Patient undergoing a change in chemotherapy within 1 day prior to or 1 day after gadopiclenol administration,
Patient who received any other contrast agent for CT and/or MRI within 1 week prior to or 1 week after gadopiclenol administration,
Patient with contraindication for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker),
Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs,
Patient with history of hypersensitivity caused by any contrast media / agents (iodinated or gadolinium-based),
Patient with known contraindication(s) to the use of any GBCA,
Pregnant or breast-feeding female patient (female patient with childbearing potential [who experienced menarche] must have a negative urine pregnancy test within 24 hours prior to gadopiclenol administration and must be using medically approved contraception* if sexually active),
Patient with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the patient's safety or her/his ability to participate to the whole trial,
Patient unlikely to comply with the protocol, e.g., uncooperative attitude of parent(s) or legal guardian, inability to return for follow-up visits and unlikelihood of completing the trial,
Having participated in a clinical trial and having received any investigational product within 7 days prior to gadopiclenol administration or planned during the trial,
Patient previously included in this trial,
Patient related to the Investigator or any other trial staff or relative directly involved in the trial conduct.
Primary purpose
Allocation
Interventional model
Masking
80 participants in 6 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal